Delving into the Latest Updates on Mycomedica Life Sciences Pbc with Synapse

概览

疾病领域	数量

肿瘤	1
免疫系统疾病	1
内分泌与代谢疾病	1
感染	1
神经系统疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor	1

关联

1

项与 Mycomedica Life Sciences Pbc 相关的药物

Psilocybin

裸盖菇素

靶点

5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor

作用机制

5-HT1A receptor拮抗剂 [+3]

在研机构

ATAI Life Sciences NV [+32]

原研机构-

在研适应症

重度抑郁症 [+40]

非在研适应症

遗忘 [+4]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

2

项与 Mycomedica Life Sciences Pbc 相关的临床试验

NCT06643637

/ Active, not recruiting临床1期

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants

MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions.
The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy, adult participants.

开始日期2024-11-08

申办/合作机构

Mycomedica Life Sciences Pbc

NCT06326606

/ Completed临床1期

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants

MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.
The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants.

开始日期2024-03-27

申办/合作机构

Mycomedica Life Sciences Pbc

100 项与 Mycomedica Life Sciences Pbc 相关的临床结果

登录后查看更多信息

0 项与 Mycomedica Life Sciences Pbc 相关的专利（医药）

登录后查看更多信息

100 项与 Mycomedica Life Sciences Pbc 相关的药物交易

登录后查看更多信息

100 项与 Mycomedica Life Sciences Pbc 相关的转化医学

登录后查看更多信息